Renal Mass Biopsy to Guide Treatment Decisions for Small Incidental Renal Tumors: A Cost-effectiveness Analysis

Authors:
  • DGDebra A. Gervais
    Debra A. Gervais
  • RHRebecca I. Hartman
    Rebecca I. Hartman
  • MHMukesh G. Harisinghani
    Mukesh G. Harisinghani
  • AFAdam S. Feldman
    Adam S. Feldman
  • PMPeter R. Mueller
    Peter R. Mueller
  • GGG. Scott Gazelle
    G. Scott Gazelle

Abstract
Our results support the use of biopsy to manage small incidentally detected renal tumors. PurposeTo evaluate the effectiveness, cost, and cost-effectiveness of using renal mass biopsy to guide treatment decisions for small incidentally detected renal tumors.Materials and MethodsA decision-analytic Markov model was developed to estimate life expectancy and lifetime costs for patients with small (≤4-cm) renal tumors. Two strategies were compared: renal mass biopsy to triage patients to surgery or imaging surveillance and empiric nephron-sparing surgery. The model incorporated biopsy performance, the probability of track seeding with malignant cells, the prevalence and growth of benign and malignant tumors, treatment effectiveness and costs, and patient outcomes. An incremental cost-effectiveness analysis was performed to identify strategy preference under a willingness-to-pay threshold of $75 000 per quality-adjusted life-year (QALY). Effects of changes in key parameters on strategy preference were evaluated in sensitivity analysis.ResultsUnder base-case assumptions, the biopsy strategy yielded ...

This publication has 68 references indexed in Scilit: